Key facts
- It has raised $130.0M; the latest was Early Stage VC ($85.0M) in Feb 2026.
- Notable investors include OrbiMed, Creacion Ventures, Gordian Ventures, Hongshan Technology, LAV (Lilly Asia Fund) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for QuantX
- ·The full record, as it builds
Funding rounds
No funding rounds for QuantX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QuantX
Developer of computational drug discovery technology designed for oral small-molecule therapeutics for immunology and inflammation. The company leverages advanced computation and modeling to accelerate the discovery of superior oral small-molecule medicines against validated immunology and inflammation targets, enabling biopharma partners and patients to benefit from faster, more efficient development of next-generation therapies.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2022
- Employees
- 24
- Website
- quantxbio.com/
- Ownership
- Privately Held (backing)
QuantX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QuantX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QuantX in its N-PORT filings yet. We sweep new filings monthly.